Tubulin polymerization-IN-2 是一种靶向β-微管蛋白的强效抗癌药物，IC50为 0.92 μM。Tubulin polymerization-IN-2 对各种白血病、非小细胞肺癌、肾癌、前列腺癌和乳腺癌细胞系显示出良好的抑制活性。

Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC 50 value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines [1].

Tubulin polymerization-IN-2 (compound 2b) shows anti-cancer activity against epidermal carcinoma and breast carcinoma with IC 50 s of 2.3 μM (KB) and 2.2 μM (BT-549), respectively [1]. Tubulin polymerization-IN-2 (0.342 μM; 24 h) inhibits DNA synthesis or repair, arrests cell cycle at S phase in MCF-7 cells [1]. Tubulin polymerization-IN-2 (0.342 μM; 24 h) induces cell apoptosis by decreasing Bax, APAF-1, and caspase-3 expression and increasing BCL-2 mRNA abundance [1]. Tubulin polymerization-IN-2 (0.01, 0.1, 1, 10 μM; 1 h) has strong interactions on β-tubulin polymerization, with K i value of 0.09 μM [1].

C17H12F2N2O2

314.29

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years